NEW YORK (GenomeWeb News) – Meridian Bioscience today reported essentially flat year-over-year sales growth for the second quarter, though adoption of its molecular diagnostic platform continued to accelerate.

For the three months ended March 31, revenues came in at $47.3 million, up a fraction of 1 percent from $47.2 million a year ago, and missing the average analyst estimate of $49.7 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.